Monday, December 10, 2018

Oleuropein as a novel anti-diabetic nutraceutical. An overview: (ADO)- Lupine Publishers



Among the cardiometabolic diseases, type 2 diabetes mellitus (T2DM) is one of the most diffused worldwide. Pharmacological treatments commonly used present several side effects, and this is driving people to search natural approaches. Olea europaea is currently investigated for its anti-diabetic potential. In particular, oleuropein (OLE), its main bioactive compound, have been demonstrated to exert interesting activities in management of T2DM, including hypoglycemic and antioxidant activities. The purpose of this manuscript is to review the available scientific evidence evaluating the role of OLE in managing T2DM.


For more Lupine publishers open access journals please visit our website
For more Diabetes Obesity Journal open access journalarticles please click here

No comments:

Post a Comment

Lupine Publishers| Semaglutide versus liraglutide for treatment of obesity

  Lupine Publishers| Journal of Diabetes and Obesity Abstract Background: Once weekly (OW) semaglutide is a glucagon-like peptide...